An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...

Suppr

超能文献

作者信息

O'Kane D

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Clin Pharmacol Ther. 2010 Dec;88(6):746-8. doi: 10.1038/clpt.2010.235.

DOI:10.1038/clpt.2010.235

PMID:21081942

Abstract

摘要

相似文献

An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...

Clin Pharmacol Ther. 2010 Dec;88(6):746-8. doi: 10.1038/clpt.2010.235.

Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.

Clin Pharmacol Ther. 2010 Dec;88(6):749-51. doi: 10.1038/clpt.2010.237.

Crunch time for multiple-gene tests.

Nature. 2007 Jan 25;445(7126):354-5. doi: 10.1038/445354a.

Implementing the U.S. FDA guidance on pharmacogenomic data submissions.

Environ Mol Mutagen. 2007 Jun;48(5):354-8. doi: 10.1002/em.20294.

The FDA is coming! The FDA is coming!

Mol Diagn. 2001 Sep;6(3):153-4. doi: 10.1054/modi.2001.0060153.

FDA perspectives on pharmacogenetic testing.

Expert Rev Mol Diagn. 2005 Sep;5(5):643-8. doi: 10.1586/14737159.5.5.643.

FDA pharmacogenomics guidance sends clear message to industry.

Nat Rev Drug Discov. 2005 May;4(5):359. doi: 10.1038/nrd1745.

Regulation: The FDA is overcautious on consumer genomics.

Nature. 2014 Jan 16;505(7483):286-7. doi: 10.1038/505286a.

Should pharmacogenomic studies be required for new drug approval?

Clin Pharmacol Ther. 2007 Mar;81(3):425-8. doi: 10.1038/sj.clpt.6100097.

How will the FDA impact the laboratory developed test?

Clin Lab Sci. 2007 Summer;20(3):130-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...

Clin Pharmacol Ther. 2010 Dec;88(6):746-8. doi: 10.1038/clpt.2010.235.

Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.

Clin Pharmacol Ther. 2010 Dec;88(6):749-51. doi: 10.1038/clpt.2010.237.

Crunch time for multiple-gene tests.

Nature. 2007 Jan 25;445(7126):354-5. doi: 10.1038/445354a.

Implementing the U.S. FDA guidance on pharmacogenomic data submissions.

Environ Mol Mutagen. 2007 Jun;48(5):354-8. doi: 10.1002/em.20294.

The FDA is coming! The FDA is coming!

Mol Diagn. 2001 Sep;6(3):153-4. doi: 10.1054/modi.2001.0060153.

FDA perspectives on pharmacogenetic testing.

Expert Rev Mol Diagn. 2005 Sep;5(5):643-8. doi: 10.1586/14737159.5.5.643.

FDA pharmacogenomics guidance sends clear message to industry.

Nat Rev Drug Discov. 2005 May;4(5):359. doi: 10.1038/nrd1745.

Regulation: The FDA is overcautious on consumer genomics.

Nature. 2014 Jan 16;505(7483):286-7. doi: 10.1038/505286a.

Should pharmacogenomic studies be required for new drug approval?

Clin Pharmacol Ther. 2007 Mar;81(3):425-8. doi: 10.1038/sj.clpt.6100097.

How will the FDA impact the laboratory developed test?

Clin Lab Sci. 2007 Summer;20(3):130-1.